Mark Zitter, Founder and CEO of The Zitter Group, in San Francisco and Millburn, NJ, discusses how oncology payers are tightening the reins with approval requirements and the delicacy involved in revising guidelines around cancer care.
Mr. Zitter talks about several of the payers' changes, which include prior authorizations, clinical guidelines, and decision-support programs. He also addresses the ongoing friction between payers and providers and how critical it is to find resolution.
Health Outcomes of Dually Eligible Beneficiaries Under Different Medicare Payment Arrangements
December 1st 2025Within the same physician groups, 2-sided risk in Medicare Advantage (MA) was associated with higher quality and lower utilization for dually eligible beneficiaries compared with fee-for-service MA and traditional Medicare.
Read More